Dr. Kimberly Lynn Levinson, MD, MPH

Dr. Levinson practices at Greater Baltimore Medical Center in Baltimore, Maryland, part of GBMC HealthCare.

Dr. Levinson's NPI, 1104028620, was assigned on June 5, 2007. Dr. Levinson graduated from Johns Hopkins University School of Medicine in 2007. Dr. Levinson holds Maryland license D77881.

Dr. Levinson's primary practice is Greater Baltimore Medical Center, at 6701 North Charles Street, Baltimore, MD 21204 in Baltimore County. The practice phone is (443) 849-2000.

Dr. Levinson's primary practice is Greater Baltimore Medical Center in Baltimore, Maryland, part of GBMC HealthCare. Dr. Levinson is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Levinson to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Levinson practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Levinson's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Levinson is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dr. Levinson is licensed in Maryland.

CMS data shows 313 Medicare services from Dr. Levinson across 8 procedure codes in 2024, for 100 Medicare patients. Medicare paid $40,330 for them.

CMS counts 100 Medicare patients who saw Dr. Levinson in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Levinson's median patient age at 64, with 99% women.

In 2024, Dr. Levinson wrote 211 Medicare Part D claims for 38 patients. 71% of them were for generic drugs. CMS names the drug for 107 of them, across 6 drugs with 11 or more claims each, at $279,862 in total drug cost. In 2023, CMS named 177 claims across 9 drugs.

CMS lists Dr. Levinson as offering telehealth. CMS counts 24 procedures of removal of the uterus by Dr. Levinson, more than 95% of the clinicians it reports for that procedure.

Dmand AI links 59 papers to Dr. Levinson, published from 2009 to 2025. 2017 was the busiest year, with 7. The most frequent topics are Ovarian Neoplasms, Uterine Cervical Neoplasms and Genital Neoplasms, Female. Dr. Levinson has published most often in Gynecol Oncol. Dr. Levinson's most frequent co-authors are Anna Louise Beavis, MD, Stephanie Wethington, MD and Sarah M. Temkin, MD.

Dmand AI links Dr. Levinson to 7 clinical trials, 3 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Carcinosarcoma, Carcinoma, Endometrioid and Fallopian Tube Diseases. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 49 general payments to Dr. Levinson from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. AstraZeneca Pharmaceuticals LP paid the most, $339.

Dr. Levinson graduated from Johns Hopkins University School of Medicine in 2007.